SLU332
SLU-PP-332
Not a peptide. A small-molecule pyrimidinone described in the literature as a pan-agonist of the estrogen-related receptors, a family of orphan nuclear receptors — intracellular transcription factors, not the cell-surface receptors most compounds in this directory act on.
No registered human study names SLU-PP-332 as an intervention. ClinicalTrials.gov holds no trial of it, so there is no trial evidence to read — a fact about the public record rather than proof the compound does nothing. No FDA-approved product contains SLU-PP-332. 10 papers naming it were published in the last ten years.
Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Counts include only trials whose registered intervention names SLU-PP-332; the registry search is fuzzy, so every match is re-checked. None of this says whether SLU-PP-332 works or is safe.
FDA status
Research only
Human studies
0
Furthest phase
—
Papers, 10 yr
10
Readership
4,136
monthly average, Feb–Jul 2026
Tracking since 2026-07-29 · About this data
What has actually been tested in humans
No registered human study
0
Registered human studies
None
No FDA-approved product contains it
No study of SLU-PP-332 in humans is registered on ClinicalTrials.gov. That is a fact about the public record, not a statement that the compound does nothing — but it does mean there is no trial evidence to read, and anyone telling you otherwise should be asked for the registration number. The grade is mechanical: it is computed from the registry and the FDA record alone, and it grades how much is known, never whether a compound is good or safe. Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Check the query.
What SLU-PP-332 is, and what it has been studied for
SLU-PP-332 is tracked here.
No registered trial names SLU-PP-332 as an intervention, so there is no condition it has been formally studied in. It does have a literature: 10 indexed papers name it in the last ten years. That work is laboratory and animal research, and a paper is not a trial.
Is anyone studying SLU-PP-332?
Papers published each year that name SLU-PP-332 in the title or abstract, with the clinical trials that started in the same year marked beneath. Ten calendar years.
| Year | Publications | Trials started | Complete year |
|---|---|---|---|
| 2017 | 0 | 0 | Yes |
| 2018 | 0 | 0 | Yes |
| 2019 | 0 | 0 | Yes |
| 2020 | 0 | 0 | Yes |
| 2021 | 0 | 0 | Yes |
| 2022 | 0 | 0 | Yes |
| 2023 | 3 | 0 | Yes |
| 2024 | 2 | 0 | Yes |
| 2025 | 2 | 0 | Yes |
| 2026 | 5 | 0 | No |
10 papers between 2017 and 2026. A paper counts when “SLU-PP-332” appears in its title or abstract — phrase-matched, so a paper mentioning the words separately is not counted. The total is a single query over the whole window, which is why it does not equal the bars added together: PubMed files a paper under both its electronic and its print publication date, so one paper can appear in two years. Publication volume measures scientific attention, not whether a compound works: a well-studied compound can be well-studied and ineffective. Sources: PubMed and ClinicalTrials.gov · collected 2026-08-02.
Published research on SLU-PP-332
10 indexed papers name SLU-PP-332 in their title or abstract. These are the 8 PubMed ranks most relevant. Listing a paper is not a judgement about it, and none of these is summarised here — follow the link and read what it says.
- A Synthetic ERR Agonist Alleviates Metabolic Syndrome
- Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function
- In Vitro Metabolism and Analytical Characterization of SLU-PP-332 and SLU-PP-915: Novel Pan-ERR Agonists With Doping Potential
- Chemical optimization of the exercise mimetic SLU-PP-332 enables insight into estrogen-related receptor signaling
- An orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity
- Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity
- Analysis and Identification of In Vitro Metabolites of Exercise Mimetic SLU-PP-332 ERRα/β/γ Agonist for Doping-Control Purposes
- Estrogen-Related Receptor Agonism Reverses Mitochondrial Dysfunction and Inflammation in the Aging Kidney
Collected 2026-08-02from PubMed, phrase-matched on “SLU-PP-332” in title and abstract. Run the same search.
About SLU-PP-332
Not a peptide. A small-molecule pyrimidinone described in the literature as a pan-agonist of the estrogen-related receptors, a family of orphan nuclear receptors — intracellular transcription factors, not the cell-surface receptors most compounds in this directory act on.
Structure and mechanism only. Nothing above describes what this compound is for, and no dose appears anywhere on this page.
Vendor listings are not affiliate links and PepRack earns nothing from them. A listing records a price we observed on a date. It is not a recommendation of a product, dose, or treatment, and PepRack does not verify what any vendor ships.